Last updated: February 20, 2026
What is the drug for?
NDC 43598-0898 corresponds to Prolia (denosumab), a monoclonal antibody indicated for osteoporosis in postmenopausal women, certain cancer treatments, and other bone-related conditions. Approved by the FDA, it has a significant presence in the osteoporotic and oncology markets.
Market Overview
Market Size and Dynamics
- Global osteoporosis drugs market: Estimated at USD 12.5 billion in 2022, expected to grow at a CAGR of 4.8% through 2030.
- Prolia's market share: Dominates the denosumab segment, with approximately 55% of sales within its class (Datamonitor, 2022).
- Key competitors: Bisphosphonates (e.g., alendronate), other monoclonal antibodies (e.g., romosozumab).
Revenue and Sales Trends
- 2022 sales: Approximate US sales of USD 3.8 billion.
- Growth drivers: Increasing osteoporosis prevalence, expanding indications (e.g., glucocorticoid-induced osteoporosis), and new formulary access.
- Pricing policies: Pricing is influenced by payer negotiations, approval of biosimilars, and regional regulatory changes.
Regulatory and Market Access Factors
- Biosimilars: Fermentation of biosimilars is underway, with phase 3 biosimilar candidates in Europe and the United States.
- Pricing trends: In the US, Prolia's list price was approximately USD 1,200 per dose in 2022, with actual net prices lower due to discounts and rebates.
Geographic Breakdown
| Region |
2022 US Sales (USD Millions) |
Market Share |
Comments |
| United States |
3,800 |
63% |
Largest market, high payer negotiations |
| Europe |
1,700 |
28% |
Market access restrictions, biosimilar entry |
| Rest of World |
300 |
9% |
Emerging markets, lower prices |
Price Projections
Short-term (2023-2025)
- Price stability: List price will remain around USD 1,200 per dose due to existing contracts.
- Influencing factors: Patent protections, payer negotiations, biosimilar entry delays.
- Reimbursement: Payers are adopting stricter formularies, decreasing net prices.
Medium-term (2026-2030)
- Biosimilar impact: Entry expected starting 2025-2026, potentially reducing list prices by 20-30%.
- Price decline estimates: Net prices could decline 15% to 25% as biosimilars mature and market saturation occurs.
- Pricing trend: List prices may decrease slightly or stabilize as market reaches equilibrium.
Long-term (2030 and beyond)
- Market saturation: Significant biosimilar penetration could reduce prices further.
- Innovation influence: Next-generation therapies may impact volume, though primary market share for denosumab may persist.
- Price floors: Likely to stabilize around USD 700-900 per dose with biosimilar competition.
Comparable Biosimilar Price Considerations
| Biosimilar Candidate |
Expected Approval |
Estimated Price Reduction |
Launch Year |
Notes |
| Amgen’s biosimilar |
2024-2025 |
20-30% |
2025 |
Pending FDA approval |
| Sandoz’s biosimilar |
2024 |
20-25% |
2025 |
European approval, US submission pending |
Key Market Movements
- The potential for biosimilar competition to disrupt pricing.
- Payer pressures leading to negotiations and rebates.
- Growth in off-label uses expanding market size.
Conclusion
Prolia maintains substantial market share driven by its efficacy and established payer coverage. Near-term prices will stabilize, with biosimilar competition initiating price declines starting 2025-2026. Further market saturation and biosimilar penetration could reduce net prices by up to 25% over the next five years, with a long-term stabilizing at USD 700-900 per dose.
Key Takeaways
- The current US list price is approximately USD 1,200 per dose.
- Biosimilar entry beginning 2025 is expected to lower prices by 20-30%.
- The global market size is USD 12.5 billion, with US leading.
- Pricing is sensitive to payer negotiations and biosimilar availability.
- Long-term prices are projected to stabilize around USD 700-900 per dose.
Frequently Asked Questions
Q1: What factors influence the price of Prolia?
A1: Market competition, biosimilar entry, payer negotiations, and regional regulatory policies.
Q2: When will biosimilar versions of denosumab enter the market?
A2: Biosimilars are likely to receive FDA approval and launch by 2025-2026.
Q3: How does biosimilar competition impact prices?
A3: Biosimilar entry typically reduces prices by 20-30%, increasing access and pressuring originator prices.
Q4: What is the outlook for long-term pricing?
A4: Prices are expected to stabilize around USD 700-900 per dose within the next decade due to biosimilar market saturation.
Q5: How does regional variability affect pricing?
A5: US prices are higher due to less regulation, while Europe and emerging markets show lower prices influenced by regional policies and payer frameworks.
References
- Datamonitor. (2022). Osteoporosis Drugs Market Report.
- FDA. (2022). Approved Drugs Database.
- Sandoz. (2022). Biosimilar Development Pipeline.
- IQVIA. (2022). US Prescription Drug Market Data.
- EvaluatePharma. (2023). Biosimilar Market Trends.
